At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 33 enrolled
Drug / intervention
Afrezza (insulin human) Inhalation Powder +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ABC [Afrezza With Basal Combination]: A Phase 4 Study of Mealtime Control With Afrezza in Adult Subjects With Type 1 Diabetes Mellitus in Combination With an Automated Insulin Pump or Insulin Degludec
In Brief
A Phase 4 clinical trial evaluating Afrezza (insulin human) Inhalation Powder, insulin degludec, and 1 other intervention for Type 1 Diabetes. Completed, enrolled 33 participants across 2 sites.
Detailed Summary
A phase 4 study evaluating the efficacy of mealtime control with Afrezza in combination with an automated insulin pump or insulin degludec in adult subjects with type 1 diabetes
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
First PostedFeb 2022
Enrollment StartMar 2022
Primary CompletionOct 2022
TodayJul 2026
First PostedFeb 17, 2022
Enrollment StartMar 31, 2022
Primary CompletionOct 17, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.4 years ago
Interventions
Afrezza (insulin human) Inhalation Powderbiological
Pharmaceutical form: powder Route of administration: inhalation
insulin degludecbiological
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)device
Acceptable AID systems in this study are Medtronic 670G/770G and Tandem Control IQ